Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial - PubMed (original) (raw)
Clinical Trial
. 2013 Apr;138(2):499-508.
doi: 10.1007/s10549-013-2473-6. Epub 2013 Mar 8.
Affiliations
- PMID: 23471651
- DOI: 10.1007/s10549-013-2473-6
Clinical Trial
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Olöf Bjarnadottir et al. Breast Cancer Res Treat. 2013 Apr.
Abstract
Lipophilic statins purportedly exert anti-tumoral effects on breast cancer by decreasing proliferation and increasing apoptosis. HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, is the target of statins. However, data on statin-induced effects on HMGCR activity in cancer are limited. Thus, this pre-operative study investigated statin-induced effects on tumor proliferation and HMGCR expression while analyzing HMGCR as a predictive marker for statin response in breast cancer treatment. The study was designed as a window-of-opportunity trial and included 50 patients with primary invasive breast cancer. High-dose atorvastatin (i.e., 80 mg/day) was prescribed to patients for 2 weeks before surgery. Pre- and post-statin paired tumor samples were analyzed for Ki67 and HMGCR immunohistochemical expression. Changes in the Ki67 expression and HMGCR activity following statin treatment were the primary and secondary endpoints, respectively. Up-regulation of HMGCR following atorvastatin treatment was observed in 68 % of the paired samples with evaluable HMGCR expression (P = 0.0005). The average relative decrease in Ki67 expression following atorvastatin treatment was 7.6 % (P = 0.39) in all paired samples, whereas the corresponding decrease in Ki67 expression in tumors expressing HMGCR in the pre-treatment sample was 24 % (P = 0.02). Furthermore, post-treatment Ki67 expression was inversely correlated to post-treatment HMGCR expression (rs = -0.42; P = 0.03). Findings from this study suggest that HMGCR is targeted by statins in breast cancer cells in vivo, and that statins may have an anti-proliferative effect in HMGCR-positive tumors. Future studies are needed to evaluate HMGCR as a predictive marker for the selection of breast cancer patients who may benefit from statin treatment.
Similar articles
- The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Butt S, Butt T, Jirström K, Hartman L, Amini RM, Zhou W, Wärnberg F, Borgquist S. Butt S, et al. Ann Surg Oncol. 2014 Sep;21(9):2911-9. doi: 10.1245/s10434-014-3708-4. Epub 2014 Apr 29. Ann Surg Oncol. 2014. PMID: 24777857 - Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
Feldt M, Bjarnadottir O, Kimbung S, Jirström K, Bendahl PO, Veerla S, Grabau D, Hedenfalk I, Borgquist S. Feldt M, et al. J Transl Med. 2015 Apr 29;13:133. doi: 10.1186/s12967-015-0486-0. J Transl Med. 2015. PMID: 25925673 Free PMC article. Clinical Trial. - Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A, Breining D, Rauner M, Hofbauer LC, Rachner TD. Göbel A, et al. Cell Death Dis. 2019 Jan 28;10(2):91. doi: 10.1038/s41419-019-1322-x. Cell Death Dis. 2019. PMID: 30692522 Free PMC article. - Statins: a role in breast cancer therapy?
Borgquist S, Bjarnadottir O, Kimbung S, Ahern TP. Borgquist S, et al. J Intern Med. 2018 Oct;284(4):346-357. doi: 10.1111/joim.12806. Epub 2018 Jul 9. J Intern Med. 2018. PMID: 29923256 Free PMC article. Review. - The effect of statins on cancer cells--review.
Matusewicz L, Meissner J, Toporkiewicz M, Sikorski AF. Matusewicz L, et al. Tumour Biol. 2015 Jul;36(7):4889-904. doi: 10.1007/s13277-015-3551-7. Epub 2015 May 23. Tumour Biol. 2015. PMID: 26002574 Review.
Cited by
- Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.
Patel KK, Kashfi K. Patel KK, et al. Biochem Pharmacol. 2022 Feb;196:114654. doi: 10.1016/j.bcp.2021.114654. Epub 2021 Jun 12. Biochem Pharmacol. 2022. PMID: 34129857 Free PMC article. Review. - An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
Longo J, Mullen PJ, Yu R, van Leeuwen JE, Masoomian M, Woon DTS, Wang Y, Chen EX, Hamilton RJ, Sweet JM, van der Kwast TH, Fleshner NE, Penn LZ. Longo J, et al. Mol Metab. 2019 Jul;25:119-130. doi: 10.1016/j.molmet.2019.04.003. Epub 2019 Apr 10. Mol Metab. 2019. PMID: 31023626 Free PMC article. - Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer.
Dehghani M, Samani Z, Abidi H, Manzouri L, Mahmoudi R, Hosseini Teshnizi S, Nikseresht M. Dehghani M, et al. Int J Genomics. 2018 Mar 22;2018:4863757. doi: 10.1155/2018/4863757. eCollection 2018. Int J Genomics. 2018. PMID: 29765975 Free PMC article. - Ultrasound-Targeted Microbubble Disruption with Key Nanodroplets for Effective Ferroptosis in Triple-Negative Breast Cancer Using Animal Model.
Liu R, Shi D, Guo L, Xiao S, Shang M, Sun X, Meng D, Zhao Y, Wang X, Li J. Liu R, et al. Int J Nanomedicine. 2023 Apr 19;18:2037-2052. doi: 10.2147/IJN.S400495. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37155504 Free PMC article. - The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Stine JE, Guo H, Sheng X, Han X, Schointuch MN, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL. Stine JE, et al. Oncotarget. 2016 Jan 5;7(1):946-60. doi: 10.18632/oncotarget.5834. Oncotarget. 2016. PMID: 26503475 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical